Soluble CD93 in serum as a marker of allergic inflammation

Hye Jung Park, Heejae Han, Sang Chul Lee, Young Woong Son, Da Woon Sim, Kyung Hee Park, Yoon Hee Park, Kyoung Yong Jeong, Jung Won Park, Jae Hyun Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. Materials and Methods: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up. Results: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-naïve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naïve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially. Conclusion: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naïve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation.

Original languageEnglish
Pages (from-to)598-603
Number of pages6
JournalYonsei medical journal
Volume58
Issue number3
DOIs
Publication statusPublished - 2017 May

Fingerprint

Asthma
Inflammation
Urticaria
Serum
Steroids
Biomarkers
Chronic Disease
Allergic Rhinitis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, H. J., Han, H., Lee, S. C., Son, Y. W., Sim, D. W., Park, K. H., ... Lee, J. H. (2017). Soluble CD93 in serum as a marker of allergic inflammation. Yonsei medical journal, 58(3), 598-603. https://doi.org/10.3349/ymj.2017.58.3.598
Park, Hye Jung ; Han, Heejae ; Lee, Sang Chul ; Son, Young Woong ; Sim, Da Woon ; Park, Kyung Hee ; Park, Yoon Hee ; Jeong, Kyoung Yong ; Park, Jung Won ; Lee, Jae Hyun. / Soluble CD93 in serum as a marker of allergic inflammation. In: Yonsei medical journal. 2017 ; Vol. 58, No. 3. pp. 598-603.
@article{713df93dec9e4b85bacd355bb8429b6e,
title = "Soluble CD93 in serum as a marker of allergic inflammation",
abstract = "Purpose: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. Materials and Methods: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-na{\"i}ve BA patients who were serially followed-up. Results: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-na{\"i}ve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-na{\"i}ve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially. Conclusion: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-na{\"i}ve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation.",
author = "Park, {Hye Jung} and Heejae Han and Lee, {Sang Chul} and Son, {Young Woong} and Sim, {Da Woon} and Park, {Kyung Hee} and Park, {Yoon Hee} and Jeong, {Kyoung Yong} and Park, {Jung Won} and Lee, {Jae Hyun}",
year = "2017",
month = "5",
doi = "10.3349/ymj.2017.58.3.598",
language = "English",
volume = "58",
pages = "598--603",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

Park, HJ, Han, H, Lee, SC, Son, YW, Sim, DW, Park, KH, Park, YH, Jeong, KY, Park, JW & Lee, JH 2017, 'Soluble CD93 in serum as a marker of allergic inflammation', Yonsei medical journal, vol. 58, no. 3, pp. 598-603. https://doi.org/10.3349/ymj.2017.58.3.598

Soluble CD93 in serum as a marker of allergic inflammation. / Park, Hye Jung; Han, Heejae; Lee, Sang Chul; Son, Young Woong; Sim, Da Woon; Park, Kyung Hee; Park, Yoon Hee; Jeong, Kyoung Yong; Park, Jung Won; Lee, Jae Hyun.

In: Yonsei medical journal, Vol. 58, No. 3, 05.2017, p. 598-603.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Soluble CD93 in serum as a marker of allergic inflammation

AU - Park, Hye Jung

AU - Han, Heejae

AU - Lee, Sang Chul

AU - Son, Young Woong

AU - Sim, Da Woon

AU - Park, Kyung Hee

AU - Park, Yoon Hee

AU - Jeong, Kyoung Yong

AU - Park, Jung Won

AU - Lee, Jae Hyun

PY - 2017/5

Y1 - 2017/5

N2 - Purpose: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. Materials and Methods: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up. Results: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-naïve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naïve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially. Conclusion: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naïve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation.

AB - Purpose: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. Materials and Methods: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up. Results: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-naïve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naïve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially. Conclusion: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naïve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=85016201423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016201423&partnerID=8YFLogxK

U2 - 10.3349/ymj.2017.58.3.598

DO - 10.3349/ymj.2017.58.3.598

M3 - Article

C2 - 28332366

AN - SCOPUS:85016201423

VL - 58

SP - 598

EP - 603

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -

Park HJ, Han H, Lee SC, Son YW, Sim DW, Park KH et al. Soluble CD93 in serum as a marker of allergic inflammation. Yonsei medical journal. 2017 May;58(3):598-603. https://doi.org/10.3349/ymj.2017.58.3.598